Market Closed -
Nasdaq
21:30:00 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
16.36
USD
|
-0.91%
|
|
+13.06%
|
+28.31%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
56.44
|
691.8
|
436.1
|
53.02
|
75.01
|
96.43
|
-
|
-
|
Enterprise Value (EV)
1 |
56.44
|
691.8
|
436.1
|
53.02
|
75.01
|
96.43
|
96.43
|
96.43
|
P/E ratio
|
-1.75
x
|
-13.4
x
|
-9.52
x
|
-0.9
x
|
-1.42
x
|
-2.64
x
|
-3.18
x
|
-3.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
63.8
x
|
40.9
x
|
5.22
x
|
7.48
x
|
11.2
x
|
10.8
x
|
8.81
x
|
EV / Revenue
|
-
|
63.8
x
|
40.9
x
|
5.22
x
|
7.48
x
|
11.2
x
|
10.8
x
|
8.81
x
|
EV / EBITDA
|
-
|
-
|
-10.4
x
|
-1
x
|
-
|
-1.96
x
|
-1.7
x
|
-1.53
x
|
EV / FCF
|
-
|
-
|
-11.6
x
|
-
|
-1.95
x
|
-2.05
x
|
-1.95
x
|
-1.82
x
|
FCF Yield
|
-
|
-
|
-8.63%
|
-
|
-51.2%
|
-48.7%
|
-51.3%
|
-55%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,660
|
4,223
|
4,580
|
4,820
|
5,883
|
5,894
|
-
|
-
|
Reference price
2 |
34.00
|
163.8
|
95.20
|
11.00
|
12.75
|
16.36
|
16.36
|
16.36
|
Announcement Date
|
19/03/20
|
16/03/21
|
24/02/22
|
13/03/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.84
|
10.65
|
10.16
|
10.02
|
8.612
|
8.963
|
10.95
|
EBITDA
1 |
-
|
-
|
-41.91
|
-52.79
|
-
|
-49.31
|
-56.83
|
-62.95
|
EBIT
1 |
-
|
-24.9
|
-42.06
|
-53.02
|
-48.33
|
-50.55
|
-55.57
|
-62.64
|
Operating Margin
|
-
|
-229.79%
|
-395.01%
|
-521.75%
|
-482.21%
|
-586.92%
|
-619.92%
|
-572.22%
|
Earnings before Tax (EBT)
1 |
-
|
-29.91
|
-45.44
|
-56.67
|
-47.41
|
-49.17
|
-53.69
|
-61.09
|
Net income
1 |
-32.14
|
-29.91
|
-45.44
|
-56.67
|
-47.41
|
-49.59
|
-54.95
|
-60.41
|
Net margin
|
-
|
-276.03%
|
-426.67%
|
-557.69%
|
-473.04%
|
-575.85%
|
-613.01%
|
-551.88%
|
EPS
2 |
-19.40
|
-12.20
|
-10.00
|
-12.20
|
-8.960
|
-6.208
|
-5.148
|
-4.843
|
Free Cash Flow
1 |
-
|
-
|
-37.62
|
-
|
-38.43
|
-47
|
-49.5
|
-53
|
FCF margin
|
-
|
-
|
-353.26%
|
-
|
-383.46%
|
-545.73%
|
-552.25%
|
-484.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
16/03/21
|
24/02/22
|
13/03/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.039
|
3.135
|
2.057
|
2.393
|
2.825
|
2.887
|
2.297
|
2.197
|
2.833
|
2.696
|
2.004
|
2.03
|
2.269
|
2.293
|
2.65
|
EBITDA
1 |
-10.01
|
-12.53
|
-15.1
|
-15.02
|
-12.54
|
-10.13
|
-11.56
|
-12.07
|
-12.3
|
-
|
-12.36
|
-12.61
|
-12.06
|
-12.29
|
-13.78
|
EBIT
1 |
-10.05
|
-12.57
|
-15.13
|
-15.06
|
-12.61
|
-10.22
|
-11.63
|
-12.14
|
-12.37
|
-12.2
|
-12.67
|
-12.68
|
-12.47
|
-12.57
|
-12.92
|
Operating Margin
|
-330.64%
|
-400.86%
|
-735.68%
|
-629.38%
|
-446.23%
|
-354%
|
-506.18%
|
-552.48%
|
-436.57%
|
-452.49%
|
-631.9%
|
-624.58%
|
-549.33%
|
-547.94%
|
-487.55%
|
Earnings before Tax (EBT)
1 |
-11.05
|
-13.62
|
-16.11
|
-15.94
|
-13.29
|
-11.33
|
-11.56
|
-11.96
|
-12.18
|
-11.71
|
-12.57
|
-12.66
|
-12.05
|
-11.89
|
-12.89
|
Net income
1 |
-11.05
|
-13.62
|
-16.11
|
-15.94
|
-13.29
|
-11.33
|
-11.56
|
-11.96
|
-12.18
|
-11.71
|
-12.6
|
-12.63
|
-12.17
|
-12.26
|
-12.89
|
Net margin
|
-363.64%
|
-434.45%
|
-783.13%
|
-666.11%
|
-470.58%
|
-392.41%
|
-503.22%
|
-544.42%
|
-429.97%
|
-434.42%
|
-628.43%
|
-622.07%
|
-536.42%
|
-534.74%
|
-486.32%
|
EPS
2 |
-2.400
|
-3.000
|
-3.600
|
-3.400
|
-2.800
|
-2.400
|
-2.400
|
-2.400
|
-2.130
|
-2.030
|
-2.050
|
-1.722
|
-1.415
|
-1.375
|
-1.200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
24/02/22
|
05/05/22
|
04/08/22
|
09/11/22
|
13/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
08/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-37.6
|
-
|
-38.4
|
-47
|
-49.5
|
-53
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.68
|
-
|
0.42
|
-
|
1
|
0.5
|
0.5
|
Capex / Sales
|
-
|
6.25%
|
-
|
4.09%
|
-
|
11.61%
|
5.58%
|
4.57%
|
Announcement Date
|
19/03/20
|
16/03/21
|
24/02/22
|
13/03/23
|
08/02/24
|
-
|
-
|
-
|
Last Close Price
16.36
USD Average target price
77.4
USD Spread / Average Target +373.11% Consensus |
1st Jan change
|
Capi.
|
---|
| +28.31% | 96.43M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|